Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C26H37N5O2
CAS Number:
Molecular Weight:
451.60
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D −63 to −74°, c = 0.5 in dichloromethane
solubility
DMSO: ≥10 mg/mL
originator
Johnson & Johnson
storage temp.
2-8°C
SMILES string
CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1
InChI
1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
InChI key
KORNTPPJEAJQIU-KJXAQDMKSA-N
Gene Information
human ... DRD2(1813)
Biochem/physiol Actions
Cabergoline, a lysergic acid amide derivative, is a potent dopamine D2 receptor agonist. It also acts on dopamine receptors in lactophilic hypothalamus cells to suppress prolactin production in the pituitary gland. It has been used for monotherapy of Parkinson′s disease in the early phase; combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson′s disease and adjunctive therapy of prolactin-producing pituitary gland tumors (microprolactinomas).
Dopamine D2-receptor agonist; Prolactin inhibitor; Antiparkinsonian
Features and Benefits
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Still not finding the right product?
Explore all of our products under Cabergoline
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Lact.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Samuel Santos-Ribeiro et al.
Journal of assisted reproduction and genetics, 32(7), 1063-1068 (2015-05-20)
We report on the results of the whole-genome analysis performed in a patient who developed severe ovarian hyperstimulation syndrome (OHSS) following gonadotropin-releasing hormone (GnRH) agonist triggering in a "freeze-all" protocol. A 30-year-old patient with polycystic ovary syndrome who developed severe
Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
Annamaria Colao et al.
Nature clinical practice. Endocrinology & metabolism, 2(4), 200-210 (2006-08-26)
Prolactinoma is the most frequent pituitary tumor histotype. Men generally have macroadenomas whereas women generally have microadenomas. The major objectives of treating prolactinomas are to suppress excessive hormone secretion and its clinical consequences, to remove the tumor mass while preserving
M C Porter et al.
International journal of clinical practice, 56(6), 468-474 (2002-08-09)
Dopamine agonists have diverse chemical and physical properties that can directly stimulate the dopamine receptors, unlike levodopa which undergoes presynaptic breakdown to dopamine before dopaminergic effects in Parkinson's disease (PD). Cabergoline, a dopamine agonist effective given once daily, is being
Global Trade Item Number
| SKU | GTIN |
|---|---|
| C0246-10MG | 04061833023716 |
| C0246-50MG | 04061833023723 |
